Combining FATP2 inhibition with immune checkpoint blockade has emerged as a promising strategy against tumor progression.[186] In immunocompetent mice, both genetic and pharmacological ferroptosis inhibitors negate the suppressive activity of PMN‐MDSCs, thereby limiting tumor growth. This evidence concerns the gene SLC27A2 and neoplasm.